36 results about "Nasolacrimal duct" patented technology

The invention provides punctal plugs for the delivery of active agent to one or both of the tear fluid of the eye and to the nasolacrimal duct. The plugs of the invention have a body, a reservoir contained within the body, and optionally a collarette. The reservoir has at least one opening and contains a polymeric material and at least one active agent.

The invention provides punctal plugs for the delivery of active agent to one or both of the tear fluid of the eye and to the nasolacrimal duct. The plugs of the invention have a body, a reservoir contained within the body, and optionally a collarette. The reservoir has at least one opening and contains a polymeric material and at least one active agent.

A device is used to temporarily compress the nasolacrimal ducts to reduce outflow of eyedrop during and after eyedrop instillation. The device is to be hand bended to snuggly fit any adult head sizes with any facial features so that the nose pads may apply firm pressure over the nasal aspect of the orbital rim where nasolacrimal ducts lay underneath the skin. The pressure delivered by the device is consistent and is controllable by the user. The device includes failure mechanism to protect against excessive pressure. By keeping eyedrops in the eye, medication absorption is improved and bitter taste due to eydrop outflow is reduced or eliminated. It alleviates the burden of manual nasolacrimal occlusion currently practiced by eye patients and is best for frequent, multiple eyedrops users.

The invention provides punctal plugs for the delivery of active agent to one or both of the tear fluid of the eye and to the nasolacrimal duct that comprise a body, at least one cap, and optionally a collarette.

The invention belongs to the field of pharmaceutical preparations, and relates to an ophthalmic gel containing travoprost and timolol and a preparation method thereof. The invention also relates to the use of said ophthalmic gel. The ophthalmic gel of the present invention increases the residence time of the two active ingredients travoprost and timolol in the eye, reduces the loss of solution eye drops in the eye, improves bioavailability, and significantly improves the Ocular irritation of the drug and systemic side effects due to nasolacrimal drainage increase the stability of ingredients (bacteriostats) that have specific effects and are used in small amounts in the formulation.

A nasolacrimal stent device illuminates a dark nasal cavity so that the interior of the nasal cavity can be directly observed to facilitate and ensure the correct insertion of a nasolacrimal stent into the nasal duct. Flexible, transparent probe tube segments (21) are connected to the opposite ends of a flexible detention tube segment (2) having a diameter that permits the flexible detention tube segment (2) to be inserted in a lacrimal passage, respectively. The respective extremities of distal end parts (21a, 21b) of the probe tube segments (21) are closed. The probe tube segments (21) are provided in their base end parts with openings (23), respectively. When inserting each probe tube segment (21) into the nasal cavity, an illuminating device, such as an optical fiber (30) is inserted through the opening (23) into the probe tube segment (21) to illuminate the interior of the nasal cavity through the transparent probe tube segment (21). The probe tube segment (21) can be surely caught with a hook and can be pulled out from the nasal cavity. An ultrasonic probe or an endoscope may be used instead of the illuminating device to find the position of the nasolacrimal stent in the nasal cavity.

A device is used to temporarily compress the nasolacrimal ducts to reduce outflow of eyedrop during and after eyedrop instillation. The device is to be hand bended to snuggly fit any adult head sizes with any facial features so that the nose pads may apply firm pressure over the nasal aspect of the orbital rim where nasolacrimal ducts lay underneath the skin. The pressure delivered by the device is consistent and is controllable by the user. The device includes failure mechanism to protect against excessive pressure. By keeping eyedrops in the eye, medication absorption is improved and bitter taste due to eyedrop outflow is reduced or eliminated. It alleviates the burden of manual nasolacrimal occlusion currently practiced by eye patients and is best for frequent, multiple eyedrops users.

Provided is a hydrogel, comprising the following raw materials in parts by weight: 10-80 parts of hydroxyethyl methacrylate, 1-20 parts of a crosslinking agent, 10-80 parts of water, and 0.042-36 parts of a reaction initiator. The crosslinking agent is at least one of poly(ethylene glycol) diacrylate, ethylene glycol dimethacrylate, and triallyl isocyanurate. The reaction initiator is a mixture of a thermal initiator and a catalyst or a photoinitiator. The hydrogel has good hydrophilic properties, strong mechanical properties, and good biocompatibility and stability in the human body. Also provided is an artificial nasolacrimal duct containing the hydrogel. The artificial nasolacrimal duct has high tear guiding efficiency and good biocompatibility and stability, can achieve a longer implantation period, and does not easily cause rejection and inflammatory reactions in long-term implantation, is capable of expanding after water absorption and achieving a self-fixation effect, and involves a simple implantation process and easy operation.

The invention discloses a nasolacrimal duct bracket for wing-shaped fixed parts, which comprises a drainage tube and at least two wing-shaped fixed parts, wherein one end of the wing-shaped fixed part is fixed at the head end of the drainage tube, while the other end extends radically and obliquely. The nasolacrimal duct bracket for the wing-shaped fixed parts has the advantages that the bracket is convenient to collect tears and drain, can maintain smooth movement of the nasolacrimal duct, has simple manufacture, and so on.

The invention discloses an artificial nasolacrimal duct which is simple in structure, capable of being led in and led out conveniently, and capable of avoiding repeated operations. The artificial nasolacrimal duct comprises an inner tube which is made of silica gel materials and a locating piece. The locating piece is arranged on the outer wall of the inner tube, and the artificial nasolacrimal duct can be supported by the locating piece to be located in a pipeline of a human body nasolacrimal duct. The inner tube is of a splicing structure of multiple channels and multiple sections. The locating piece either can be a section of spiral band which is made of degradable and expandable materials and arranged on the outer wall of the inner tube or can be an outer pipe which is arranged on the outer wall of the inner tube and made of degradable and expandable materials. The locating piece can further comprise a locating groove and an absorbable line. The spiral locating groove is formed in the outer wall of the inner tube, the absorbable line is wound in the locating groove, the maximum external diameter of the wound absorbable line is slightly larger than the external diameter of the inner tube, so that the absorbable line is in direct contact with the inner wall of the human body nasolacrimal duct, and thus the effect that the artificial nasolacrimal duct is located in the human body nasolacrimal duct through the absorbable line can be achieved.

The present invention relates to a nasolacrimal duct insertion member comprising a shape memory polymer for treatment of nasolacrimal duct obstruction / stenosis, wherein the shape memory polymer comprises a crosslinkable functional group, such that the nasolacrimal duct insertion member has a melting point suitable for implantation into a living body.

The invention provides a biological retina, which is applied to tissue repair in the field of ophthalmological department. The tissue repair includes glaucoma trabeculectomy, a neovascular glaucoma surgery, uveitic glaucoma, a pterygium surgery, a strabismus surgery, a nasolacrimal duct operation, an orbital surgery, an ocular plastic surgery, a conjunctival scar tissue reconstruction surgery, a burn repair surgery and a corneal ulcer surgery; and the preparation method comprises the following steps: preparing a high-purity type I collagen and glacial acetic acid water solution according to a preset proportion and emulsifying; and vacuumizing the emulsified slurry and freeze-drying the slurry so as to obtain a collagen film having a three-dimensional porous structure. The biological retina disclosed by the invention has beneficial effects that the prepared biological retina, which takes the collagen, as a major ingredient, is good in biocompatibility and biodegradability and is capable of controlling an inflammatory reaction; the high-purity collagen is free from antigenicity and repellency; by virtue of the three-dimensional porous structure, the random and discrete hyperplasia of fibroblasts is guided; and the biological retina can inhibit conjunctival scars and conjunctival contraction, and can keep normal intraocular pressure.

The invention relates to the field of lacrimal duct diagnosis and treatment, in particular to a lacrimal duct diagnosis and treatment auxiliary device and its application. The structure of the device is as follows: a part of the side wall of the flexible channel forms an outwardly expanding expansion; the device channel is arranged inside the flexible channel, a part of the side walls of the device channel also forms an outwardly expanding expansion, and the expanding part of the device channel is located in the flexible channel. In the enlarged part of the channel, one end of the device channel extends to the outside of the rear end of the flexible channel. The traction part includes a first through hole, a second through hole and a pulling wire, the first through hole and the second through hole are respectively arranged on the side wall of the flexible passage near the front end and the rear end, and one end of the pulling wire passes through the second through hole. The hole is bound at the rear end of the flexible channel, and the other end of the pulling wire extends from the inside of the flexible channel to the first through hole and passes through the first through hole. The device can establish a flexible channel between the nostril and the lacrimal canaliculus for instrument access and protection of the nasolacrimal duct, thereby successfully introducing various therapeutic devices and improving the effect of examination and treatment.

The invention discloses a degradable medical composite conduit containing a functional nano coating and a preparation method thereof, which is characterized in that the composite conduit is in a three-layer structure, wherein an inner layer and a middle layer are formed through the melt extrusion compounding by a medical-conduit precision extruder, an outer layer is formed by spraying a degradable high-molecular material dissolved with an effective quantity of active medicaments to the outside of a double-layer composite pipe, and the thickness of the outer layer does not exceed 300nm. The conduit not only overcomes the deficiencies of a metal medical conduit, but also well controls the medicament releasing speed and the conduit degrading speed through a composite structure, is mainly applied to the interventional therapies of trachea, bronchus, esophagus, alimentary canals, bile ducts, nasolacrimal ducts and the like and has broad application prospect.